新型抗血小板药普拉格雷在冠心病应用中的研究进展

被引：18

作者：

李贤峰

王兆君

机构：

[1] 解放军海军总医院心内科

来源：

临床军医杂志 | 2009年 / 37卷 / 01期

关键词：

抗血小板药; 普拉格雷; 冠心病;

D O I：

暂无

中图分类号：

R541.4 [冠状动脉（粥样）硬化性心脏病（冠心病）];

学科分类号：

100201 [内科学];

摘要：

普拉格雷是新一代强效噻蒽并吡啶类抗血小板药。通过对健康志愿者的观察及在稳定性心绞痛和急性冠状动脉综合征介入手术中应用,发现其比氯吡格雷有更快更强更持久的抗血小板作用,能显著减少缺血事件的发生率,但出血的危险性有所增加。在临床使用中应注意识别血栓高危患者和出血风险高危人群。

引用

页码：125 / 126

页数：2

共 8 条

[1]

Increased active metabolite formation explains the greater platelet inhibition with prasugrel compared to high-dose clopidogrel [J].

Payne, Christopher D. ;

Li, Ying Grace ;

Small, David S. ;

Ernest, C. Steven, II ;

Farid, Nagy A. ;

Jakubowski, Joseph A. ;

Brandt, John T. ;

Salazar, Daniel E. ;

Winters, Kenneth J. .

JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2007, 50 (05) :555-562

[2]

Comparison of speed of onset of platelet inhibition after loading doses of clopidogrel versus prasugrel in healthy volunteers and correlation with responder status [J].

Weerakkody, Govinda J. ;

Jakubowski, Joseph A. ;

Brandt, John T. ;

Farid, Nagy A. ;

Payne, Christopher D. ;

Zhu, Jianyu ;

Warner, Margaret R. ;

Naganuma, Hideo ;

Winters, Kenneth J. .

AMERICAN JOURNAL OF CARDIOLOGY, 2007, 100 (02) :331-336

[3]

A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation [J].

Brandt, John T. ;

Payne, Christopher D. ;

Wiviott, Stephen D. ;

Weerakkody, Govinda ;

Farid, Nagy A. ;

Small, David S. ;

Jaknbowski, Joseph A. ;

Naganuma, Hideo ;

Winters, Kenneth J. .

AMERICAN HEART JOURNAL, 2007, 153 (01) :66.e9-66.e16

[4]

Platelet inhibitory activity and pharmacokinetics of prasugrel (CS-747) a novel thienopyridine P2Y<sub>12</sub> inhibitor: A single ascending dose study in healthy humans?.[J].Fumitoshi Asai;Joseph A. Jakubowski;Hideo Naganuma;John T. Brandt;Nobuko Matsushima;Takashi Hirota;Stephen Freestone;Kenneth J. Winters.Platelets.2006, 4

[5]

Platelet inhibitory activity and pharmacokinetics of prasugrel (CS-747) a novel thienopyridine P2Y<sub>12</sub> inhibitor: A multiple-dose study in healthy humans?.[J].Nobuko Matsushima;Joseph A. Jakubowski;Fumitoshi Asai;Hideo Naganuma;John T. Brandt;Takashi Hirota;Stephen Freestone;Kenneth J. Winters.Platelets.2006, 4

[6]

Randomized Comparison of Prasugrel (CS-747; LY640315); a Novel Thienopyridine P2Y12 Antagonist; With Clopidogrel in Percutaneous Coronary Intervention: Results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)–TIMI 26 Trial.[J].Stephen D. Wiviott;Elliott M. Antman;Kenneth J. Winters;Govinda Weerakkody;Sabina A. Murphy;Bruce D. Behounek;Robert J. Carney;Charles Lazzam;Raymond G. McKay;Carolyn H. McCabe;Eugene Braunwald.Circulation.2005, 25

[7]

Pharmacology of CS-747 (Prasugrel, LY640315), a novel, potent antiplatelet agent with in vivo P2Y12 receptor antagonist activity [J].

Niitsu, Y ;

Jakubowski, JA ;

Sugidachi, A ;

Asai, F .

SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2005, 31 (02) :184-194

[8]

Durability of platelet inhibition by Clopidogrel [J].

Gurbel, PA ;

Bliden, KP .

AMERICAN JOURNAL OF CARDIOLOGY, 2003, 91 (09) :1123-1125

← 1 →